Traceability applications based on Discovery Services

RFID, in its different forms, but especially following EPCglobal standards, has become a key enabling technology for many applications. An essential component to develop track and trace applications in a complex multi-vendor scenario are the Discovery Services. Although they are already envisaged as part of the EPCglobal network architecture, the functional definition and standardization of the Discovery Service is still at a very early stage. Within the scope of the BRIDGE project, a specification for the interfaces of Discovery Services has been developed, together with a prototype to validate the design and different models to enhance supply-chain control through track and trace applications. © 2008 IEEE.

Security considerations in the design and peering of RFID discovery services

There is growing interest in Discovery Services for locating RFID and supply chain data between companies globally, to obtain product lifecycle information for individual objects. Discovery Services are heralded as a means to find serial-level data from previously unknown parties, however more realistically they provide a means to reduce the communications load on the information services, the network and the requesting client application. Attempts to design a standardised Discovery Service will not succeed unless security is considered in every aspect of the design. In this paper we clearly show that security cannot be bolted-on in the form of access control, although this is also required. The basic communication model of the Discovery Service critically affects who shares what data with whom, and what level of trust is required between the interacting parties. © 2009 IEEE.

Anti HIV-1 Agents 2. Discovery of Dibenzofurans as New HIV-1 Inhibitors In Vitro

Ten dibenzofurans were synthesized and evaluated as human immunodeficiency virus (HIV)-1 inhibitors in vitro for the first time. Among these compounds, compounds 1, 6, 7 and 8 demonstrated significant anti-HIV-1 activity. Especially compound 1 showed the

Anti Human Immunodeficiency Virus-1 (HIV-1) Agents 1. Discovery of Benzyl Phenyl Ethers as New HIV-1 Inhibitors in Vitro

Ten single benzyl phenyl ethers were synthesized and evaluated as human immunodeficiency virus-1 (HIV-1) inhibitors in vitro for the first time. Among these compounds, especially 4-nitrobenzyl phenyl ether (3h) exhibited the highest anti-HIV-1 activity wi

Anti Human Immunodeficiency Virus Type 1 (HIV-1) Agents 4. Discovery of 5,5 '-(p-Phenylenebisazo)-8-hydroxyquinoline Sulfonates as New HIV-1 Inhibitors in Vitro

To search for compounds with superior anti-human immunodeficiency virus type 1 (HIV-1) activity, ten 5,5'-(p-phenylenebisazo)-8-hydroxyquinoline sulfonates (4a-j) were synthesized and preliminarily evaluated as HIV-1 inhibitors in vitro for the first time. Some compounds demonstrated anti-HIV-1 activity, especially 5,5'-(p-phenylenebisazo)-8-hydroxyquinoline p-ethylbenzenesulfonate (4g) and 5,5'-(p-phenylenebisazo)-8-hydroxyquinoline p-chlorobenzenesulfonate (41) showed the more potent anti-HIV-1 activity with 50% effective concentration (EC50) values of 2.59 and 4.01 mu g/ml, and therapeutic index (TI) values of 31.77 and 24.51, respectively.